Onyx maintained by Merrill at neutral

Onyx Pharmaceuticals, Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating. Based on a broader label and 60% higher-than-expected price for Nexavar, Nexavar sales estimates were raised to $144 million from $104 million in 2006. The key risks are Pfizer's competitive drug Sutent and low visibility on co-promotion expenses, but weaknesses following potential approval of Sutent may be an opportunity. Shares of the Emeryville, Calif., biopharmaceutical company were up 40 cents, or 1.39%, at $29.25 on volume of 961,914 shares versus the three-month running average of 1,073,160 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.